Poland· PL-100285212
Mepact
A mifamurtid product containing mifamurtidum, registered in Poland by Esteve Pharmaceuticals, S.A.. The same ATC class is registered in 8 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Mifamurtid is registered in 8 of 19 countries.
Countries holding a registration under ATC L03AX15 (mifamurtid), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Mifamurtid · ATC L03AX15
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Mifamurtidum
- Manufacturer
- Esteve Pharmaceuticals, S.A.
- Country
- Poland (PL)
- ATC code
- L03AX15
- ATC class
- Mifamurtid
- Defined daily dose
- 0.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909991004552
- gtin08053677610012
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mifamurtid in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomMepact 4mg powder for concentrate for dispersion for infusion vialsTakeda UK Ltd
- BelgiumMepact 4 mgEsteve Pharmaceuticals
- FinlandMEPACTEsteve Pharmaceuticals, S.A
- IrelandMepact 4 mg Powder for concentrate for dispersion for infusionEsteve Pharmaceuticals S.A.
- SwedenMEPACT 4 mg Pulver till koncentrat till infusionsvätska, dispersionEsteve Pharmaceuticals S.A.
- CzechiaMEPACTEsteve Pharmaceuticals S.A., Barcelona
- SpainMEPACT 4 mg POLVO PARA SUSPENSION PARA PERFUSIONEsteve Pharmaceuticals S.A.
- IcelandMepactEsteve Pharmaceuticals S.A.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Mepact
- Liechtenstein · Mepact
- Norway · Mepact
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0a4b30ac-2718-41f9-b241-3785791a7a85 GET /v1/drugs/0a4b30ac-2718-41f9-b241-3785791a7a85?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania koncentratu dyspersji do infuzji",
"source": "urpl",
"strength": "4 mg",
"packaging": "05909991004552 ¦ Rpz ¦ EU/1/08/502/001 ¦ 78993\n1 fiol. 4 mg proszku + 1 filtr\n¦ UR/Z/4c/064/26 - 08053677610012",
"substance": "Mifamurtidum 4 mg",
"common_name": "Mifamurtidum",
"pl_product_id": "100285212",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about mifamurtid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.